Management of Pre-eclampsia and HELLP Syndrome

Diagnosis and Assessment

HELLP syndrome should be considered a manifestation of severe pre-eclampsia, characterized by hemolysis, elevated liver enzymes, and low platelet count 1
Comprehensive maternal assessment should include blood pressure monitoring and proteinuria evaluation, complete blood count with platelet count, liver function tests, evaluation for hemolysis, and coagulation studies 1, 3, 4
Abnormal liver tests frequently correlate with adverse maternal outcomes but should not be used in isolation to guide management 1

The American College of Cardiology recommends initiating oral antihypertensive therapy using labetalol, nifedipine, or methyldopa for non-severe hypertension 1, 2, 3
For severe hypertension, treatment should be initiated urgently in a monitored setting with oral labetalol, nifedipine, or methyldopa, and consider intravenous labetalol or hydralazine if rapid control is needed 1, 2, 3
Hydralazine dosing should be 5 mg IV bolus, then 10 mg every 20-30 minutes to a maximum of 25 mg, and labetalol dosing should be 20 mg IV bolus, then 40 mg 10 minutes later, followed by 80 mg every 10 minutes for 2 additional doses to a maximum of 220 mg 3

Magnesium sulfate should be administered to all women with HELLP syndrome with co-existing severe hypertension to prevent eclamptic seizures, and as a neuroprotective agent for preterm pre-eclampsia if delivery is required before 32 weeks' gestation 1, 2
Dosing should follow local or national guidelines, such as those from the American College of Obstetricians and Gynecologists 1

Platelet transfusion should be considered in pregnant women with platelet count <100×10⁹/L due to increased risk of abnormal coagulation and adverse maternal outcomes 1, 5
For Caesarean section, platelet transfusion is recommended if platelet count is <50,000/mm³, according to guidelines from the American Society of Anesthesiologists 6, 7, 8

Corticosteroid treatment should not be given to improve maternal outcomes in HELLP syndrome, as recommended by the Society for Maternal-Fetal Medicine 1, 2
High-dose dexamethasone or betamethasone should be administered to improve fetal lung maturity if delivery is anticipated before 35 weeks' gestation, following guidelines from the American College of Obstetricians and Gynecologists 1, 2

Prompt delivery is indicated once maternal coagulopathy and severe hypertension have been corrected, as recommended by the American College of Obstetricians and Gynecologists 1, 2
Immediate delivery is recommended in cases of severe thrombocytopenia, according to guidelines from the British Society for Haematology 7

Patients should be monitored in a high-dependency or intensive care setting for at least 24-48 hours post-delivery, with monitoring including central venous pressure, urinary output, blood pressure, ECG, and oxygen saturation, as recommended by the Society of Critical Care Medicine 4, 8
Liver function and platelet counts typically normalize within days to weeks after delivery, according to the American Association for the Study of Liver Diseases 8

Abdominal ultrasound should be performed if symptoms suggest hepatic hematoma, as recommended by the American Institute of Ultrasound in Medicine 1, 2
Be vigilant for hepatic complications, especially with severe thrombocytopenia, according to guidelines from the American Association for the Study of Liver Diseases 1, 2

Women with a history of prior HELLP syndrome should undergo first-trimester screening to assess risk of early-onset pre-eclampsia, as recommended by the American College of Obstetricians and Gynecologists 1
For high-risk women, aspirin prophylaxis (150 mg nightly) should be started before 16 weeks' gestation and continued until 36 weeks, delivery, or diagnosis of pre-eclampsia/HELLP, according to guidelines from the U.S. Preventive Services Task Force 1, 2
In women with low calcium intake (<800 mg/day), calcium supplementation (1.5-2 g elemental calcium/day) may reduce the risk of both early and late-onset pre-eclampsia, as recommended by the National Institutes of Health 1, 2